Skandinaviska Enskilda Banken (SEB)’s Corcept Therapeutics CORT Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-43,600	Closed	-$1.42M	–	828
2023 Q4	$1.42M	Hold	43,600	–	–	0.01%	643
2023 Q3	$1.19M	Sell	43,600 -9,000	-17%	-$260K	0.01%	652
2023 Q2	$1.17M	Sell	52,600 -53,500	-50%	-$1.23M	0.01%	677
2023 Q1	$2.3M	Buy	+106,100	New	+$2.33M	0.02%	519
2021 Q2	–	Sell	-22,800	Closed	-$542K	–	1059
2021 Q1	$542K	Sell	22,800 -3,900	-15%	-$104K	﹤0.01%	918
2020 Q4	$698K	Sell	26,700 -77,200	-74%	-$1.63M	﹤0.01%	869
2020 Q3	$1.81M	Buy	103,900 +32,200	+45%	+$513K	0.01%	594
2020 Q2	$1.21M	Buy	+71,700	New	+$1.01M	0.01%	688

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s CORT Position: Q1 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 43,600 shares — an estimated $1.42M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in CORT in Q2 2020 and held it in 8 quarters. The position peaked at $2.3M in Q1 2023. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

Skandinaviska Enskilda Banken (SEB) reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 43,600 Corcept Therapeutics shares in Q1 2024, an estimated $1.42M.
Skandinaviska Enskilda Banken (SEB) first reported a position in Corcept Therapeutics in Q2 2020 and held it in 8 quarters.
Skandinaviska Enskilda Banken (SEB)'s Corcept Therapeutics position peaked at $2.3M in Q1 2023.
287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2024, filed 13 May 2024.